On the other hand, the preliminary and promising preclinical and clinical studies testing either Foxp3+ TREG cell therapy or complexed IL-2 suggest that Foxp3+ TREG are definitely an interesting therapeutic target for AIH and probably also for NASH patients. The gene discussed is FOXP3; the disease is metabolic dysfunction-associated steatohepatitis.